Angelo Ravelli: Influence Statistics

Angelo Ravelli

Angelo Ravelli

Dipartimento di Neuroscienze, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, ITALY | Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Dipartimento di ...

Angelo Ravelli: Expert Impact

Concepts for which Angelo Ravelli has direct influence: Juvenile idiopathic arthritis , Macrophage activation syndrome , Inactive disease , Idiopathic arthritis , Juvenile dermatomyositis , Juvenile idiopathic , Radiographic progression .

Angelo Ravelli: KOL impact

Concepts related to the work of other authors for which for which Angelo Ravelli has influence: Juvenile idiopathic arthritis , Macrophage activation syndrome , Systemic lupus erythematosus , Rheumatic diseases , Patients jia , Kawasaki disease .

KOL Resume for Angelo Ravelli

Year
2022

Dipartimento di Neuroscienze, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, ITALY

Direzione Scientifica, Istituto Giannina Gaslini Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico, Genova, Italy

RITA, European Reference Networks, Brussels, Belgium

Sechenov First Moscow State Medical University, Moscow, Russian Federation

2021

Department of Pediatric Rheumatology, Sechenov First Moscow State Medical University, Moscow, Russian

Università degli Studi di Genova, Dipartimento di Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno‐Infantili, Genova, Italy

Clinic of Pediatrics and Rheumatology, IRCCS G. Gaslini and University of Genoa.

2020

Department of Paediatric Rheumatology, Gaslini Children's Hospital, Genoa, Italy

IRCCS Istituto Giannina Gaslini - Paediatric Rheumatology International Trials Organisation (PRINTO)

2019

Gaslini Children’s Hospital, Genoa, Italy

2018

A. Martini, MD, Professor, IRCCS Istituto Giannina Gaslini, Direzione Scientifica; A. Ravelli, MD, Professor, IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia and Università degli Studi di Genova; T. Avcin, MD, PhD, University Children's Hospital, University Medical Center Ljubljana, Department of Allergology, Rheumatology and Clinical Immunology; M.W. Beresford, MBChB, PhD, Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, and Institute of Translational Medicine, University of Liverpool; R. Burgos-Vargas, MD, Hospital General de Mexico, Departamento de Reumatología; R. Cuttica, MD, Hospital Pedro de Elizalde, Rheumatology Section; N.T. Ilowite, MD, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Pediatrics; R. Khubchandani, MD, Jaslok Hospital and Research Centre, Department of Paediatrics; R.M. Laxer, MD, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto; D.J. Lovell, MD, MPH, Cincinnati Children's Hospital Medical Center, Division of Rheumatology; R.E. Petty, MD, PhD, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia; C.A. Wallace, MD, Seattle Children's Hospital; N.M. Wulffraat, MD, PhD, Wilhelmina Children's Hospital, Department of Pediatric Immunology and Rheumatology; A. Pistorio, MD, PhD, IRCCS Istituto Giannina Gaslini, Servizio di Epidemiologia e Biostatistica; N. Ruperto, MD, MPH, IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO.

From Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Direzione Scientifica; IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Pediatric Rheumatology International Trials Organization (PRINTO), and Università degli Studi di Genova; IRCCS Istituto Giannina Gaslini, Servizio di Epidemiologia e Biostatistica, Genoa, Italy; University Children's Hospital, University Medical Center Ljubljana, Department of Allergology, Rheumatology and Clinical Immunology, Ljubljana, Slovenia; Department of Paediatric Rheumatology, Alder Hey Children's National Health Service (NHS) Foundation Trust; Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Hospital General de Mexico, Departamento de Reumatología, Mexico City, Mexico; Hospital Pedro de Elizalde, Rheumatology Section, Buenos Aires, Argentina; Children's Hospital at Montefiore, Albert Einstein College of Medicine, Pediatrics, New Hyde Park, New York; Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, Ohio; Seattle Children's Hospital, Seattle, Washington, USA; Jaslok Hospital and Research Centre, Department of Paediatrics, Mumbai, India; The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, Ontario; British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada; Wilhelmina Children's Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, the Netherlands.

Istituto G. Gaslini, Pediatria II-Reumatologia, Genova, Italy.

Dipartimento di Pediatria, Università di Genova, Genoa, Italy

2017

Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Pediatric Rheumatology and Pediatric Health Services Research, University of Michigan CS Mott Children's Hospital, Ann Arbor, Michigan; Office of Research, Division of Rheumatology, Columbia University Medical Center, New York; Division of Rheumatology, University of Rochester, Golisano Children's Hospital, Rochester, New York; Thornhill Associates, Hermosa Beach; Division of Immunology/Rheumatology, Stanford University, Stanford, California; Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Arthritis Foundation, Atlanta, Georgia; Division of Rheumatology, Children's Mercy, Kansas City, Missouri; Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey; Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Rheumatology, Seattle Children's Hospital, Seattle, Washington; Johns Hopkins Arthritis Center, Johns Hopkins University, Baltimore, Maryland, USA; Division of Rheumatology, Istituto Giannina Gaslini; University of Genoa, Genoa, Italy; Rheumatology, Royal Children's Hospital; Murdoch Children's Research Institute, Melbourne, Australia; The Hospital for Sick Children, and Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto; Children's Hospital of Eastern Ontario Research Institute, Department of Pediatrics and School of Rehabilitation Sciences, University of Ottawa, Ottawa, Ontario, Canada.

University of Genova, Genoa, Italy

Prominent publications by Angelo Ravelli

KOL-Index: 14679 . OBJECTIVE: To characterize disease activity patterns in a large cohort of children with juvenile idiopathic arthritis (JIA), by applying newly developed preliminary definitions of inactive disease, clinical remission on medication, and clinical remission off medication. METHODS: Children with persistent or extended oligoarthritis, polyarthritis (either rheumatoid factor [RF] positive or RF ...
Known for Clinical Remission | Inactive Disease | Select Categories | 5 Years
KOL-Index: 14540 . OBJECTIVE: To validate and promulgate a core set of outcome measures for the evaluation of response to treatment in patients with juvenile systemic lupus erythematosus (SLE). METHODS: In 2001, a preliminary consensus-derived core set of measures for evaluating the response to therapy in juvenile SLE was established. In the present study, the core set was validated through an ...
Known for Response Therapy | Lupus Erythematosus | Prospective Validation | Juvenile Systemic
KOL-Index: 13763 . OBJECTIVE: To investigate the level of agreement between patients, mothers, fathers, and physicians in rating pain intensity in juvenile idiopathic arthritis (JIA), and to identify factors explaining discrepancies between raters. METHODS: Ninety-four children with JIA and their mothers and fathers were asked to rate independently the intensity of present pain and pain in the previous week ...
Known for Pain Children | Juvenile Idiopathic Arthritis | Mothers Fathers | Level Agreement
KOL-Index: 13620 . OBJECTIVE: To use the Pediatric Rheumatology International Trials Organization (PRINTO) core set of outcome measures to develop a validated definition of improvement for the evaluation of response to therapy in juvenile systemic lupus erythematosus (SLE). METHODS: Thirty-seven experienced pediatric rheumatologists from 27 countries, each of whom had specific experience in the assessment of ...
Known for Lupus Erythematosus | Provisional Criteria | Juvenile Systemic | Rheumatology International
KOL-Index: 13484 . Childhood-onset systemic lupus erythematosus (cSLE) is a rare, multisystem and potentially life-threatening autoimmune disorder with significant associated morbidity. Evidence-based guidelines are sparse and management is often based on clinical expertise. SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) was launched to optimise and disseminate management regimens ...
Known for Based Recommendations | Lupus Erythematosus | Onset Systemic | Share Initiative
KOL-Index: 13155 . CONTEXT: Novel therapies have improved the remission rate in chronic inflammatory disorders including juvenile idiopathic arthritis (JIA). Therefore, strategies of tapering therapy and reliable parameters for detecting subclinical inflammation have now become challenging questions. OBJECTIVES: To analyze whether longer methotrexate treatment during remission of JIA prevents flares after ...
Known for 12 Months | Methotrexate Withdrawal | Patients Jia | Juvenile Idiopathic Arthritis
KOL-Index: 12909 . BACKGROUND: In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile dermatomyositis (JDM) is a rare disease within the group of paediatric rheumatic diseases (PRDs) and can lead to ...
Known for Based Recommendations | Juvenile Dermatomyositis | Treatment Jdm | 80 Agreement
KOL-Index: 12816 . BACKGROUND: Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatomyositis. METHODS: We did a randomised trial at 54 centres in 22 ...
Known for Juvenile Dermatomyositis | Prednisone Methotrexate | Clinical Remission | Agents Child
KOL-Index: 12807 . BACKGROUND: Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the ...
Known for Patients Tocilizumab | Humanized Arthritis | Nonsteroidal Antibodies | Systemic Juvenile
KOL-Index: 12365 . OBJECTIVE: To identify a core set of outcome variables for the assessment of children with juvenile arthritis (JA), to use the core set to develop a definition of improvement to determine whether individual patients demonstrate clinically important improvement, and to promote this definition as a single efficacy measure in JA clinical trials. METHODS: A core set of outcome variables was ...
Known for Definition Improvement | Juvenile Arthritis | Core Outcome Variables | Sensitivity Specificity
KOL-Index: 12281 . OBJECTIVE: To investigate the proxy-reported health-related quality of life (HRQOL) and its determinants in patients with juvenile idiopathic arthritis (JIA). METHODS: In this multinational, multicenter, cross-sectional study, HRQOL of patients with JIA was assessed through the Child Health Questionnaire (CHQ) and was compared with that of healthy children of similar age from the same ...
Known for Hrqol Patients | Life Cohort Study | Idiopathic Arthritis | Healthy Children
KOL-Index: 11984 . OBJECTIVE: To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA). METHODS: This was an international, multicenter, randomized, placebo-controlled, double-blind study. One hundred twenty-two children with persistent polyarticular JRA despite prior methotrexate (MTX) therapy were randomized to receive infliximab or placebo for 14 weeks, ...
Known for Patients Infliximab | Juvenile Rheumatoid Arthritis | Mtx Placebo | Acr Pedi
KOL-Index: 11717 . OBJECTIVES: Interferon-γ (IFNγ) is the pivotal mediator in murine models of primary haemophagocytic lymphohistiocytosis (pHLH). Given the similarities between primary and secondary HLH (sec-HLH), including macrophage activation syndrome (MAS), we investigate the involvement of the IFNγ pathway in MAS by evaluating levels of IFNγ and of the induced chemokines, and their relation with ...
Known for Macrophage Activation | Levels Ifnγ | Patients Active Sjia | Systemic Juvenile

Key People For Juvenile Idiopathic Arthritis

Top KOLs in the world
#1
Ross Edward Petty
juvenile idiopathic arthritis systemic lupus erythematosus rubella virus
#2
Anne Marie Prieur
juvenile chronic arthritis body composition growth hormone
#3
Taunton R Southwood
juvenile idiopathic arthritis young people united kingdom
#4
David N Glass
juvenile rheumatoid arthritis gene expression calcium supplementation
#5
Alberto Martini
juvenile idiopathic arthritis inactive disease macrophage activation syndrome
#6
Prudence Joan Manners
juvenile arthritis growing pains severe hemophilia

Dipartimento di Neuroscienze, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, ITALY | Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DIN